观察！芯片巨头内讧升级！Arm与高通为何反目成仇？

芯片巨头内讧升级！Arm与高通为何反目成仇？

北京 - Arm与高通两大芯片巨头之间的战争仍在持续升级，这场始于两年前的诉讼案，如今已经发展到双方针锋相对、毫不退让的地步。究竟是什么原因导致了昔日合作伙伴的兵戎相见？

导火索：骁龙X系列处理器的强势崛起

2022年，高通推出了基于Nuvia团队设计的骁龙X系列处理器，旨在将Arm架构芯片引入PC领域。骁龙X系列处理器的强势表现，迅速抢占了部分市场份额，并对英特尔x86架构处理器构成了威胁。

利益之争：授权费纠纷和市场竞争

Arm作为Arm架构的授权方，希望能够从高通销售的每颗骁龙X处理器中收取授权费。然而，高通则认为，其已经为Arm架构支付了授权费，并拥有自行设计芯片的权利。

除了授权费纠纷之外，两家公司在PC芯片市场上也存在着直接的竞争关系。Arm希望能够借助骁龙X系列处理器，推动Arm架构在PC领域的普及，而高通则希望能够凭借其在移动芯片领域的优势，在PC市场站稳脚跟。

诉讼战：两败俱伤的结局？

为了阻止高通销售骁龙X系列处理器，Arm向法院提起了诉讼，并要求禁售所有搭载该芯片的Windows笔记本电脑。如果Arm赢得诉讼，这将对Arm架构在PC领域的推广造成重大打击。

然而，高通也坚决反对Arm的诉讼请求，并表示将捍卫自身的合法权益。这场诉讼战最终可能会导致两败俱伤的结局， both Arm and Qualcomm could suffer significant financial losses.

行业影响：芯片格局生变？

Arm与高通之间的诉讼，不仅是两家公司之间的商业纠纷，也对整个芯片行业产生了重大影响。这场诉讼可能会导致芯片产业格局生变，并加速Arm架构在PC领域的普及。

未来展望：和解仍是希望？

尽管Arm与高通之间的矛盾依然尖锐，但双方也并非完全没有和解的可能性。一些分析人士认为，两家公司最终可能会达成和解协议，以避免进一步的法律诉讼和商业损失。

这场芯片巨头之间的内讧，最终将会如何收场？让我们拭目以待。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.